•
Jul 02, 2021

Danaher Q2 2021 Earnings Report

Reported a strong second quarter with significant revenue and earnings growth.

Key Takeaways

Danaher Corporation announced strong second quarter 2021 results, with a 36.5% increase in revenues to $7.2 billion and net earnings of $1.7 billion, or $2.28 per diluted common share, representing an 84.0% year-over-year increase. Non-GAAP adjusted diluted net earnings per common share were $2.46, a 71.0% increase over the comparable 2020 period. The company anticipates non-GAAP core revenue growth in the mid- to high-teens percent range for the third quarter and approximately 20% for the full year 2021.

Revenues increased 36.5% year-over-year to $7.2 billion.

Net earnings were $1.7 billion, or $2.28 per diluted common share, an 84.0% year-over-year increase.

Non-GAAP adjusted diluted net earnings per common share were $2.46, a 71.0% increase over the comparable 2020 period.

Operating cash flow was $2.1 billion, a 46.5% increase year-over-year, and non-GAAP free cash flow was $1.8 billion, a 41.0% increase year-over-year.

Total Revenue
$7.22B
Previous year: $5.3B
+36.3%
EPS
$2.46
Previous year: $1.44
+70.8%
Core Sales Growth
31.5%
Previous year: 3.5%
+800.0%
Gross Profit
$4.4B
Previous year: $2.85B
+54.1%
Cash and Equivalents
$7.32B
Previous year: $5.54B
+32.2%
Free Cash Flow
$1.82B
Previous year: $1.3B
+39.7%
Total Assets
$78B
Previous year: $71.3B
+9.5%

Danaher

Danaher

Forward Guidance

The Company anticipates that non-GAAP core revenue growth will be in the mid- to high-teens percent range for the third quarter 2021. For the full year 2021, the Company now anticipates that the non-GAAP core revenue growth rate including Cytiva will be approximately 20%.